Hansa Biopharma AB (publ) (STO:HNSA)

Market Cap	3.26B +102.3%
Revenue (ttm)	222.27M +29.7%
Net Income	-529.25M
EPS	-6.52
Shares Out	101.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	363,613
Average Volume	458,354
Open	33.40
Previous Close	33.80
Day's Range	32.00 - 33.42
52-Week Range	19.58 - 42.98
Beta	1.84
RSI	40.60
Earnings Date	Feb 11, 2026

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 125
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: HNSA

Financial Performance

In 2025, Hansa Biopharma AB's revenue was 222.27 million, an increase of 29.74% compared to the previous year's 171.32 million. Losses were -529.25 million, -34.44% less than in 2024.